Published:
Cadence Pharmaceuticals' CEO Theodore Schroeder to Present at the 2008 NewsMakers In the Biotech Industry Conference
SAN DIEGO, Aug. 27 /PRNewswire-FirstCall/ -- Cadence Pharmaceuticals, Inc.
(Nasdaq: CADX), a biopharmaceutical company focused on in-licensing,
developing and commercializing proprietary product candidates principally for
use in the hospital setting, announced today that the company's President and
CEO Theodore Schroeder will present the company's corporate overview on
Thursday, September 4 at 4:00pm Eastern Time (1:00pm Pacific Time) during the
2008 NewsMakers In the Biotech Industry Conference at the Millennium Broadway
Hotel inNew York City.
The presentation will be simultaneously webcast and can be accessed on
Cadence Pharmaceuticals' website at http://www.cadencepharm.com in the
Investor Relations section. A replay of the webcast will be available
approximately three hours following the live webcast and will be archived for
90 days.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a biopharmaceutical company focused on
in-licensing, developing and commercializing proprietary product candidates
principally for use in the hospital setting. The company currently has two
Phase III product candidates in development, Acetavance(TM) (intravenous
acetaminophen) for the treatment of acute pain and fever, and Omigard(TM)
(omiganan pentahydrochloride 1% topical gel) for the prevention of
catheter-related infections. For more information about Cadence's pipeline,
visit http://www.cadencepharm.com.
Cadence(TM), Acetavance(TM) and Omigard(TM) are trademarks of Cadence
Pharmaceuticals, Inc.
Contacts:
William R. LaRue Anna Gralinska
SVP & Chief Financial Officer Director, Investor Relations
Cadence Pharmaceuticals, Inc. Cadence Pharmaceuticals, Inc.
858-436-1400 858-436-1452
SOURCE Cadence Pharmaceuticals, Inc.
Copyright © 2009, PRNewswire
Copyright © 2009, NewsBlaze,
Daily NewsTags: ,HEA,MTC,BIO,TDS,CCA,CA-Cadence-Newsmakers
Search News
Daily News
